Recursion reports Q3 2026 results, extends cash runway and shares positive REC‑4881 and REC‑1245 data
+4 new sources since this summary was written
Recursion Pharmaceuticals announced third‑quarter 2026 results, narrowing its net loss to $119.0 million and reporting revenue of $18.55 million, driven by a $10 million Sanofi milestone. The company presented Phase 2 data for REC‑4881 in familial adenomatous polyposis showing deep, durable polyp reductions, and Phase 1 data for REC‑1245 with a 91.7% disease‑control rate. It also appointed Fred Hassan as chair of the board and reiterated cash‑operating‑expense guidance of less than $375 million for 2026 and less than $360 million for 2027, extending its cash runway into 2029.
Why it matters
The company expects its cash resources to fund operations into 2029, according to the filing. The narrowed loss and milestone payment improve liquidity, while the clinical readouts could de‑risk its pipeline and support future financing.
Key facts
- 1Net loss for Q3 2026 shrank to $119.0 million from $162.3 million YoY. rttnews.com
- 2Revenue increased to $18.55 million, up from $5.18 million YoY. rttnews.com
- 3A $10 million Sanofi milestone payment was received during the quarter. rttnews.com
- 4REC‑4881 achieved ≥65% polyp‑burden reduction in nearly 50% of upper‑GI patients and in more than one‑third of lower‑GI patients after 12 weeks. rttnews.com
- 5Twelve weeks after stopping REC‑4881, 85% of evaluable patients remained below baseline polyp burden. rttnews.com
- 6REC‑1245 showed a 91.7% disease‑control rate (11 of 12 patients) at doses ≥45 mg. rttnews.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.